Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients

Kyung A. Hyun, Kiho Kwon, Hyunju Han, Seung Il Kim, Hyo il Jung

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are dissociated from primary tumor and circulate in peripheral blood. They are regarded as the genesis of metastasis. Isolation and enumeration of CTCs serve as valuable tools for cancer prognosis and diagnosis. However, the rarity and heterogeneity of CTCs in blood makes it difficult to separate intact CTCs without loss. In this paper, we introduce a parallel multi-orifice flow fractionation (p-MOFF) device in which a series of contraction/expansion microchannels are placed parallel on a chip forming four identical channels. CTCs were continuously isolated from the whole blood of breast cancer patients by hydrodynamic forces and cell size differences. Blood samples from 24 breast cancer patients were analyzed (half were from metastatic breast cancer patients and the rest were from adjuvant breast cancer patients). The number of isolated CTCs varied from 0 to 21 in 7.5. ml of blood. Because our devices do not require any labeling processes (e.g., EpCAM antibody), heterogeneous CTCs can be isolated regardless of EpCAM expression.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalBiosensors and Bioelectronics
Volume40
Issue number1
DOIs
Publication statusPublished - 2013 Feb 15

Fingerprint

Circulating Neoplastic Cells
Microfluidics
Fractionation
Labels
Tumors
Cells
Breast Neoplasms
Equipment and Supplies
Blood
Hydrodynamics
Cell Size
Orifices
Microchannels
Antibodies
Neoplasms
Labeling
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biomedical Engineering
  • Biotechnology
  • Electrochemistry

Cite this

@article{5153d20120ca430aa6da7ad9fdc4d903,
title = "Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients",
abstract = "Circulating tumor cells (CTCs) are dissociated from primary tumor and circulate in peripheral blood. They are regarded as the genesis of metastasis. Isolation and enumeration of CTCs serve as valuable tools for cancer prognosis and diagnosis. However, the rarity and heterogeneity of CTCs in blood makes it difficult to separate intact CTCs without loss. In this paper, we introduce a parallel multi-orifice flow fractionation (p-MOFF) device in which a series of contraction/expansion microchannels are placed parallel on a chip forming four identical channels. CTCs were continuously isolated from the whole blood of breast cancer patients by hydrodynamic forces and cell size differences. Blood samples from 24 breast cancer patients were analyzed (half were from metastatic breast cancer patients and the rest were from adjuvant breast cancer patients). The number of isolated CTCs varied from 0 to 21 in 7.5. ml of blood. Because our devices do not require any labeling processes (e.g., EpCAM antibody), heterogeneous CTCs can be isolated regardless of EpCAM expression.",
author = "Hyun, {Kyung A.} and Kiho Kwon and Hyunju Han and Kim, {Seung Il} and Jung, {Hyo il}",
year = "2013",
month = "2",
day = "15",
doi = "10.1016/j.bios.2012.07.021",
language = "English",
volume = "40",
pages = "206--212",
journal = "Biosensors and Bioelectronics",
issn = "0956-5663",
publisher = "Elsevier Limited",
number = "1",

}

Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients. / Hyun, Kyung A.; Kwon, Kiho; Han, Hyunju; Kim, Seung Il; Jung, Hyo il.

In: Biosensors and Bioelectronics, Vol. 40, No. 1, 15.02.2013, p. 206-212.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients

AU - Hyun, Kyung A.

AU - Kwon, Kiho

AU - Han, Hyunju

AU - Kim, Seung Il

AU - Jung, Hyo il

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Circulating tumor cells (CTCs) are dissociated from primary tumor and circulate in peripheral blood. They are regarded as the genesis of metastasis. Isolation and enumeration of CTCs serve as valuable tools for cancer prognosis and diagnosis. However, the rarity and heterogeneity of CTCs in blood makes it difficult to separate intact CTCs without loss. In this paper, we introduce a parallel multi-orifice flow fractionation (p-MOFF) device in which a series of contraction/expansion microchannels are placed parallel on a chip forming four identical channels. CTCs were continuously isolated from the whole blood of breast cancer patients by hydrodynamic forces and cell size differences. Blood samples from 24 breast cancer patients were analyzed (half were from metastatic breast cancer patients and the rest were from adjuvant breast cancer patients). The number of isolated CTCs varied from 0 to 21 in 7.5. ml of blood. Because our devices do not require any labeling processes (e.g., EpCAM antibody), heterogeneous CTCs can be isolated regardless of EpCAM expression.

AB - Circulating tumor cells (CTCs) are dissociated from primary tumor and circulate in peripheral blood. They are regarded as the genesis of metastasis. Isolation and enumeration of CTCs serve as valuable tools for cancer prognosis and diagnosis. However, the rarity and heterogeneity of CTCs in blood makes it difficult to separate intact CTCs without loss. In this paper, we introduce a parallel multi-orifice flow fractionation (p-MOFF) device in which a series of contraction/expansion microchannels are placed parallel on a chip forming four identical channels. CTCs were continuously isolated from the whole blood of breast cancer patients by hydrodynamic forces and cell size differences. Blood samples from 24 breast cancer patients were analyzed (half were from metastatic breast cancer patients and the rest were from adjuvant breast cancer patients). The number of isolated CTCs varied from 0 to 21 in 7.5. ml of blood. Because our devices do not require any labeling processes (e.g., EpCAM antibody), heterogeneous CTCs can be isolated regardless of EpCAM expression.

UR - http://www.scopus.com/inward/record.url?scp=84868659815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868659815&partnerID=8YFLogxK

U2 - 10.1016/j.bios.2012.07.021

DO - 10.1016/j.bios.2012.07.021

M3 - Article

VL - 40

SP - 206

EP - 212

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

SN - 0956-5663

IS - 1

ER -